// App-Quantinova.ai

: IMPACT: Healthcare resource use data and associated costs for single-inhaler triple therapy versus dual therapies in Spain

Researchers

Presenter

  • Victoria Paly

Principal Investigators

  • Laura Amanda Vallejo-Aparicio

  • Andrea Gabrio

  • Gianluca Baio

  • Alan Martin

  • Afisi Ismaila

Medical Centers

  • Perelman School of Medicine, Philadelphia, United States of America

  • GlaxoSmithKline, Uxbridge, United Kingdom

  • GlaxoSmithKline plc, Collegeville, United States of America

  • Kings College London, London, United Kingdom

  • GlaxoSmithKline plc, Madrid, Spain

Locations

  • United States

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Fluticasone furoate

  • Umeclidinium

  • Fluticasone

  • Azelastine/fluticasone propionate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • NCT02164513

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved